The high prevalence of hypertension in Indonesia encourages studies related to how the quality of life of patients with hypertension. The purpose of this study was to measure the quality of life, identify, and explain factors related to the quality of life of patients with hypertension. The study design was an associative descriptive design using a cross-sectional study approach. The study subjects were all outpatient hypertensive patients from several health centers in Bandar Lampung. The instrument used in this study was the Indonesian SF-36. The data collected included the patient demographic characteristics, including gender, age, education, occupation, and marital status, and the fields related to the medical history of the study subjects, including the duration of hypertension, complications, and the number of antihypertensive drugs consumed. Data were analyzed using the bivariate analysis to see the association between two use of them. Multivariate analysis was conducted to study the association of several independent variables with one or several dependent variables. The results of the univariate analysis showed that age, marital status, duration of illness, complications, and the number of drugs consumed affected the quality of life of hypertensive patients (p<0.05). The results of multivariate analysis showed that the factors of age, marital status, and duration of hypertension were factors that influenced the physical domain. In contrast, whereas gender, marital status, duration of hypertension, complications, and the number of drugs were influential factors in the mental domain.

A total of 26.6% of the population in Lampung Province consumed traditional medicine, one of which was Jamu Pegal Linu. However, a large public interest in herbal products was often misused by herbal manufacturers that it was possible to add BKO (Medicinal Chemicals), such as dexamethasone.The purpose of this study was to identify the presence or absence of dexamethasone in the preparation of Jamu Pegal Linu. The samples were taken from the store and depot herbs contained in the Markets of Bandar Lampung, acquired three different brands. The method used is Thin Layer Chromatography using dichloroethanediethyl ether-methanol-water (77:15: 8:1,2) as a mobile phase which were non-polar, and silica gel GF 254nm as a stationary phase. The result showed that the detection of three samples of Jamu Pegal Linu contained staining purple and the difference of Rf sample with reference standard on the first repetition is 0.46, 0.44, 0.47, and on the second repetition is 0.45, 0.45 and 0.48, which are ≥ 0.05. It can be concluded that the sample of Jamu Pegal Linu in Bandar Lampung 0% containing dexamethasone.

Crude Palm Oil (CPO) is one of the typical Indonesian plant that has potential effect as an antioxidant preparation. The purpose of this study was to produce microemulsion with CPO content that had good physical characteristics and also showed antioxidant activity. This research was divided into 3 stages i.e. microemulsion formulation, physical characterization and stability, and antioxidant activity evaluation. The microemulsion was formulated using Phase Titration Method with CPO as oil phase, surfactant tween 80, cosurfactant PEG 400 and aquadest. The treatment in this study was the addition of CPO with various concentration of 5%, 7.5%, and 10% (w/w). The optimum formula was A1 which contained 5% (w/w) CPO. The results showed that this formula had a globule size of 288.87 ± 20.94 nm, zeta potential of -0.36 mV, density of 1.024 ± 6.15x10-5 g/mL, and pH in the range of 4.5-6.5. The microemulsion was stable in storage for 28 days at 25ºC, stable against extreme temperature changes and agitation. The CPO-based microemulsion had IC50 value of 10.5 μg/mL which showed strong antioxidant activity. It can be concluded that CPO-based microemulsion had good physical stability and antioxidant activity for further cosmetic preparation.

Background: Despite the benefits of trastuzumab in many trials, evidence of its impact on health-related quality of life (HRQoL) in early treatment has not been summarized. This study explored the effects of trastuzumab treatment on HRQoL, including pooled meta-analysis, in an effort to provide an integrated assessment of HRQoL for Her2-positive early breast cancer patients.Methods: A comprehensive literature review to February 2023 using three databases, focusing on treatment using trastuzumab during the early stage, was performed. The mean changes from baseline during and after treatment were extracted from the included randomized control trials (RCTs) papers and total HRQoL scores were obtained from cross-sectional studies included. Mean difference (MD) and 95% confidence intervals were assessed by a random effect or fixed effect model based on heterogeneity (I2).Results: A total of ten studies were identified and reviewed, consisting of seven RCTs and three cross-sectional studies. The pooled analysis of the mean change from baseline during treatment resulted in an MD of 1.92 (95% CI = 1.59 to 2.25, p &lt; 0.05, I2 = 0%), favoring the trastuzumab group. A non-significant result of the mean change from baseline after treatment appeared in the analysis of 12-month follow-up. In the cross-sectional studies, pooled analyses of HRQoL showed that trastuzumab meaningfully demonstrated an improved HRQoL profile (MD = 9.29, 95% CI = 1.31 to 17.27, p = 0.02, I2 = 0%).Conclusion: Trastuzumab as a targeted therapy resulted in a favorable effect on HRQoL in the early stages of Her2-positive breast cancer. The findings of significant improvements in patients’ HRQoL and less clinically meaningful deterioration in side effects of trastuzumab-containing regimen during treatment were supported by prolonged survival.